Pamela Maher, senior staff scientist and the lead researcher of the study at Salk’s Cellular Neurobiology Laboratory said: “We had already shown that in normal animals, fisetin can improve memory.” She continued, “What we showed here is that it also can have an effect on animals prone to Alzheimer’s.”
The mice used in the study had genetic mutations that increased their susceptibility to Alzheimer’s disease. The genetically compromised mice were divided into two groups. One group was given food with the addition of fisetin at 3 months of age, while the control group was not given any fisetin with their food.
At 9-months, the mice not fed fisetin began performing poorly in memory mazes. “Those who did eat the antioxidant-enhanced food, however, performed on par with normal mice through their entire first year.”
The researchers used a preventive model, Maher explains, “We started the mice on the drugs before they had any memory loss. But obviously, human patients don’t go to the doctor until they are already having memory problems.” Clinical trials are needed to see if fisetin can reverse pre-existing memory deficits in human subjects.
Maher and her team of scientists have determined more than a decade ago that fisetin exerted a protective anti-aging effect on neurons. Follow-up studies in vitro (cell cultures) and in vivo (mice) revealed that fisetin activated a cellular pathway associated with memory and that it had both anti-inflammatory and antioxidant properties.
“Scientists studying fisetin (also called flavonoid 3,7,3′,4′-tetrahydroxyflavone) say it has positive effects on a number of cellular signalng pathways associated with brain aging. Research shows that fisetin protects nerve cells from age-related damage, including damage from stroke.
Fisetin works via specific pathways to boost production of glutathione, an antioxidant that studies have shown prevents oxidative damage to brain and nerve cells. Fisetin also preserves mitochondrial production and reduces levels of peroxynitrite, a free radical that damages neurons,” writes Melanie Haiken for Forbes.
Scientists had already discovered that fisetin has significant potential for treating diabetes and has anti-cancer potential. What’s most intriguing is that fisetin did not inhibit the formation of amyloyd plaques, conglomerates of proteins found in the brain of those with Alzheimer’s.
Previously, scientists had postulated amyloid plaque as the causative factor in Alzheimer’s disease, yet fisetin was able to effectively halt the primary symptoms associated with Alzheimer’s without targeting these plaques.
Perhaps amyloyd plaques merely correlate with Alzheimer’s and are not a causative factor, as a few other recent studies have implied.